Sotrovimab Lowers the Risk of <scp>COVID</scp> ‐19 Related Hospitalization or Death in a Large Population Cohort in the United Arab Emirates-Reference-Cited by-同舟云学术

Sotrovimab Lowers the Risk of COVID ‐19 Related Hospitalization or Death in a Large Population Cohort in the United Arab Emirates

Published:2022-07-22 Issue:6 Volume:112 Page:1214-1223
ISSN:0009-9236
Container-title:Clinical Pharmacology & Therapeutics
language:en
Short-container-title:Clin Pharma and Therapeutics

Author:

Saheb Sharif‐Askari Fatemeh¹^ORCID,Ali Hussain Alsayed Hawra²^ORCID,Tleyjeh Imad³⁴⁵⁶^ORCID,Saheb Sharif‐Askari Narjes¹^ORCID,Al Sayed Hussain Ali²,Saddik Basema¹⁷^ORCID,Hamid Qutayba¹⁸⁹,Halwani Rabih¹⁸¹⁰^ORCID

Affiliation:

1. Sharjah Institute of Medical Research University of Sharjah Sharjah United Arab Emirates

2. Pharmacy Dubai Health Authority Dubai United Arab Emirates

3. Infectious Diseases Section, Department of Medical Specialties King Fahad Medical City Riyadh Saudi Arabia

4. College of Medicine Alfaisal University Riyadh Saudi Arabia

5. Division of Infectious Diseases Mayo Clinic College of Medicine and Science Rochester Minnesota USA

6. Division of Epidemiology Mayo Clinic College of Medicine and Science Rochester Minnesota USA

7. Department of Family and Community Medicine College of Medicine, University of Sharjah Sharjah United Arab Emirates

8. Department of Clinical Sciences College of Medicine, University of Sharjah Sharjah United Arab Emirates

9. Meakins‐Christie Laboratories Research Institute of the McGill University Health Center Montreal Quebec Canada

10. Prince Abdullah Ben Khaled Celiac Disease Chair, Department of Pediatrics Faculty of Medicine, King Saud University Riyadh Saudi Arabia

Funder

Deanship of Scientific Research, King Saud University

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cpt.2700

Reference21 articles.

1. Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab

2. Remdesivir for the Treatment of Covid-19 — Final Report

3. Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients

4. Molnupiravir — A Step toward Orally Bioavailable Therapies for Covid-19

5. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Sotrovimab in the treatment of coronavirus disease-2019 (COVID-19): a systematic review and meta-analysis of randomized clinical trials;Naunyn-Schmiedeberg's Archives of Pharmacology;2024-07-20

2. Unveiling therapeutic dynamics: An in-depth comparative analysis of neutralizing monoclonal antibodies and favipiravir in alleviating COVID-19 outpatients impacts among middle-aged and special populations (MA-FAST);Journal of Infection and Public Health;2024-07

3. Exploring the Pathophysiology of Long COVID: The Central Role of Low-Grade Inflammation and Multisystem Involvement;International Journal of Molecular Sciences;2024-06-09

4. Risk factors and early preventive measures for long COVID in non-hospitalized patients: analysis of a large cohort in the United Arab Emirates;Public Health;2024-05

5. GRADE concept 6: a novel application of external indirect evidence into GRADE ratings of evidence certainty in network meta-analysis;Journal of Clinical Epidemiology;2023-11